Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
BioNTech Completes Acquisition of Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, Maryland
BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the closing […]
4D Biomaterials Completes £1.6m ($2.2m) Seed Round
4D Biomaterials has just completed a £1.6m ($2.2m) seed investment round led by DSW Ventures […]
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 Million Doses of COVID-19 Vaccine
Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today […]
UKCloud Health Launches Initiative to Support NHS Data Strategy
UKCloud Health, the multi-cloud experts who help health and care organisations advance their digital maturity […]
NHS COVID-19 App Updated to Notify Fewer Contacts to Isolate
The public is being urged to continue to use the NHS COVID-19 app as changes […]
OPEN Health Acquires Medical Communications Agency Spirit
OPEN Health has today announced the acquisition of North West UK-based medical communications agency Spirit. […]
Sanofi to Acquire Translate Bio; Advances Deployment of mRNA Technology Across Vaccines and Therapeutics Development
As part of Sanofi’s endeavor to accelerate the application of messenger RNA (mRNA) to develop […]
Wellbeing Platform 87% Raises £1.6million in Funding in Just Two Weeks
Leading workplace wellbeing platform 87% has raised £1.6 million in seed funding to accelerate its […]
Exscientia Builds Automated Laboratories in Oxford to Expand Pipeline
Exscientia today announced the opening of a 21,000 square foot expansion of its facilities at […]
SynOx Therapeutics Further Strengthens Team with Appointments of Chief Medical Officer and Chief Technology Officer
SynOx Therapeutics Limited (“SynOx” or the “Company”), the late-stage clinical biopharmaceutical company developing emactuzumab for […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more